American Century Companies Inc. lifted its position in Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 3.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,181,109 shares of the company’s stock after purchasing an additional 36,583 shares during the period. American Century Companies Inc.’s holdings in Ionis Pharmaceuticals were worth $59,410,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of the company. Rothschild Asset Management Inc. lifted its stake in Ionis Pharmaceuticals by 10.8% in the third quarter. Rothschild Asset Management Inc. now owns 281,068 shares of the company’s stock worth $14,250,000 after acquiring an additional 27,426 shares during the period. Bank of Nova Scotia purchased a new stake in Ionis Pharmaceuticals in the second quarter worth $1,526,000. Candriam Luxembourg S.C.A. lifted its stake in Ionis Pharmaceuticals by 30.0% in the third quarter. Candriam Luxembourg S.C.A. now owns 143,000 shares of the company’s stock worth $7,250,000 after acquiring an additional 33,000 shares during the period. Envestnet Asset Management Inc. lifted its stake in Ionis Pharmaceuticals by 12.3% in the third quarter. Envestnet Asset Management Inc. now owns 51,094 shares of the company’s stock worth $2,590,000 after acquiring an additional 5,594 shares during the period. Finally, AXA purchased a new stake in Ionis Pharmaceuticals in the third quarter worth $5,202,000. Hedge funds and other institutional investors own 91.44% of the company’s stock.

Ionis Pharmaceuticals Inc (NASDAQ:IONS) opened at $46.75 on Friday. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. The company has a market capitalization of $5,750.00, a price-to-earnings ratio of 333.93 and a beta of 2.53. Ionis Pharmaceuticals Inc has a 52-week low of $37.26 and a 52-week high of $65.51.

IONS has been the subject of a number of research analyst reports. Zacks Investment Research raised Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $62.00 price target for the company in a research note on Friday, October 27th. BidaskClub raised Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, December 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. BMO Capital Markets raised their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Finally, Morgan Stanley raised their price target on Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. Four analysts have rated the stock with a sell rating, six have given a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $50.76.

In other news, CFO Elizabeth L. Hougen sold 2,724 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $51.76, for a total value of $140,994.24. Following the completion of the transaction, the chief financial officer now owns 17,224 shares of the company’s stock, valued at approximately $891,514.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Chairman Stanley T. Crooke sold 22,000 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $50.01, for a total value of $1,100,220.00. Following the completion of the transaction, the chairman now directly owns 58,014 shares of the company’s stock, valued at approximately $2,901,280.14. The disclosure for this sale can be found here. Insiders have sold 133,885 shares of company stock valued at $7,002,841 in the last three months. Insiders own 2.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at https://theolympiareport.com/2018/02/11/ionis-pharmaceuticals-inc-ions-stake-lifted-by-american-century-companies-inc.html.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.